What the business is, and whether it's a good one at a fair price.
Manufactures and markets pharmaceutical formulations across critical care, women's health, and aesthetics, alongside bulk drugs (APIs). In the segment data for the year-to-date period ending September 2018, the Pharma (formulations) stream was 92.4% of segment revenue at ₹159.06 cr with EBIT of ₹29.11 cr, while Bulk Drugs was 7.1% at ₹12.15 cr. Operating scale includes a lyophilised injectables plant at Indore that reached 30% capacity utilisation and EBITDA breakeven in Q4 FY26, with 40 tech transfers completed, 27 in the pipeline, 200+ state FDA approvals, and an EU GMP certificate pending from a December 2025 audit. The international business is shifting from distributor-held to in-house marketing authorisations via an Ireland-based subsidiary, with new approvals in Myanmar, Philippines, South Africa, Colombia, Germany and Ecuador, and a global-health partnership covering 109 countries. On the domestic side, the women's health franchise holds category leadership in Ferticare and recorded its strongest year in gonadotropins; the aesthetics franchise sits at #2 in Indian botulinum toxin with ~23% share (~3.5-4% of revenue), and a Canadian filler/biostimulator in-licensing deal targets a Q3-Q4 FY27 launch. Q4 FY26 revenue was ₹252 cr (the strongest quarter on record); full-year FY26 revenue was ₹940.5 cr (+14.7% YoY) with EBITDA margin at 16.26%. Materials are the largest cost at 45.1% of revenue, followed by employee cost (16.1%), other opex (23.3%) and depreciation (3.3%). Gross debt sits around ₹400 cr against ~₹75 cr cash, with ₹20 cr per year of replacement capex and no greenfield spend planned for the next two years.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from GUFIC BIOSCIENCES LTD.'s filed financials and exchange disclosures
GUFIC BIOSCIENCES LTD. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol GUFICBIO.
Yes. Over the trailing twelve months GUFIC BIOSCIENCES LTD. reported a net profit of ₹73 Cr on revenue of ₹981 Cr.
Yes. The dividend yield is 0.02% at the current price. It paid out 2% of its profit as dividend in FY26.
No. Debt stands at 0.58× equity, and it carries net debt of ₹323 Cr. That is lower than 14% of its 171 Pharmaceuticals peers.
On trailing P/E, GUFIC BIOSCIENCES LTD. ranks 137 of 169 in Pharmaceuticals — cheaper than 19% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session GUFIC BIOSCIENCES LTD. moves 1.42% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by GUFIC BIOSCIENCES LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
